INTERNATIONAL IMMUNOPHARMACOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2022-06-25 ms9000000418821437

偏重的研究方向：药理学;炎症
经验分享：6月24号submit 记录一下

449 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2024-02-06 14778916m81暂无昵称来自广东省

偏重的研究方向：免疫;药理学;炎症
经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……

15 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2023-10-20 viviaya 来自重庆

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：免疫;炎症
经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞

36 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2022-09-15 ms4000001076782729

偏重的研究方向：口腔;炎症反应
经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌

43 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2022-12-01 visionary6 来自江西省

记录一下 2022年11月30日投稿

41 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2023-05-15 小甜甜66 来自湖北省

这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。

27 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2022-12-15 146a7280m09暂无昵称来自四川省

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：炎症;基础药理;神经
经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了

48 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2023-03-22 ms8000001972745472 来自河南省

3.11 投稿
3.12 with editor
3.13 under review
3.21 一个审稿人接受审稿

34 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2022-09-01 拉阿拉121212

偏重的研究方向：免疫;炎症
经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗

48 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1228571, encodeId=828712285e1cc, content=偏重的研究方向：药理学;炎症 经验分享：6月24号submit 记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=449, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=68345397047, createdName=ms9000000418821437, createdTime=Sat Jun 25 10:21:14 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186259, encodeId=31eb21862594e, content=偏重的研究方向：免疫;药理学;炎症 经验分享：12.16日投稿，隔天under review，12.30第一个审稿人审回，一直到今天都木找到第二个审稿人……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04fe5219567, createdName=14778916m81暂无昵称, createdTime=Tue Feb 06 21:11:26 CST 2024, time=2024-02-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163865, encodeId=734f21638659a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：免疫;炎症 经验分享：效率很高，来还愿了，耶耶耶… 6.30投稿 9.22小修 10.12修回 10.19接收审稿花了3个月，是因为一直没找到审稿人。公众号上我一直在关注，总共邀请了9个审稿人，才终于有2个审稿。两次从审稿人接受审稿到完成审稿，都是刚好2星期，我估计是杂志有时间限制。而且审稿一结束，当天就收到返修意见，效率方面我是相当的满意。返修之后，在10月这种投稿高峰期能7天给结果，我认为也很快了，赞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI64l0IicibOfsgqfemdpq8fT5wO32W4WBX7MPfmT5IxVSOwwzOichZIlM0nkOCWzZSs2m9cQ5DcibIiaQ/132, createdBy=d7af2250612, createdName=viviaya, createdTime=Fri Oct 20 05:15:25 CST 2023, time=2023-10-20, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1249028, encodeId=2e4412490280d, content=偏重的研究方向：口腔;炎症反应 经验分享：8月15号投的，现在还在外审，已完成的审稿人已经有2+了，但是还没有给意见，好慌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72028228946, createdName=ms4000001076782729, createdTime=Thu Sep 15 09:26:51 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103675, encodeId=61ce21036e565, content=记录一下 2022年11月30日投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8a5429528, createdName=visionary6, createdTime=Thu Dec 01 10:39:34 CST 2022, time=2022-12-01, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2133819, encodeId=230921338191f, content=这个杂志编辑有毛病吧。。。小修还要送外审？？？？关键是第一次返修审稿人1接收，审稿人2小修。。。结果修回去后，我看到编辑又邀请你了这两个审稿人。。。简直是大病把。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=小甜甜66, createdTime=Mon May 15 03:08:20 CST 2023, time=2023-05-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2106156, encodeId=9d7f2106156f1, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：炎症;基础药理;神经 经验分享：10.18投稿 10.22 送审 11.6两个审稿人审稿完成 11.13给大修 11.16修回 11.17再次送审 11.29审稿完成 12.1通知录用内容充实，贴合杂志范畴，创新工作做得好机会很大。先前一篇文章被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/08/ac1ab5b662c7792c750763409836166e.jpg, createdBy=e1855155890, createdName=146a7280m09暂无昵称, createdTime=Thu Dec 15 10:38:39 CST 2022, time=2022-12-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2121046, encodeId=d3fc21210466d, content=3.11 投稿 3.12 with editor 3.13 under review 3.21 一个审稿人接受审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad808404158, createdName=ms8000001972745472, createdTime=Wed Mar 22 09:55:44 CST 2023, time=2023-03-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1242556, encodeId=c8f31242556c9, content=偏重的研究方向：免疫;炎症 经验分享：7月19号投稿，到目前为止还在外审，只有一个审稿专家完成审稿，这个杂志是必须有两个审稿专家完成审稿才可以有初审意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=def85491660, createdName=拉阿拉121212, createdTime=Thu Sep 01 21:10:44 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149083, encodeId=cf08214908324, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：免疫;药理 经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44145384186, createdName=胡大镝, createdTime=Fri Jul 21 02:59:15 CST 2023, time=2023-07-21, status=1, ipAttribution=广东省)]

2023-07-21 胡大镝来自广东省

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：免疫;药理
经验分享：6月6日投稿，当天下午under review，7月6日收到大修，两个审稿人，20条意见，都不是很犀利，7月13日修回，7月20日上午显示审稿人审稿完成，当天下午就接收！杂志编辑速度真的好给力！审稿人也很友好！

20 9

展开9条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务